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Althoughthephysiologicalfunctionofthecellularprionprotein(PrPC)remainsunknown,severalevidencessupportthenotionof
itsroleincopperhomeostasis.PrPC bindsCu2+ throughadomaincomposedbyfourtoﬁverepeatsofeightaminoacids.Previously,
wehaveshownthattheperfusionofthisdomainpreventsandreversestheinhibitionbyCu2+ oftheadenosinetriphosphate(ATP)-
evokedcurrentsintheP2X4 receptorsubtype,highlightingamodulatoryroleforPrPC insynaptictransmissionthroughregulation
of Cu2+ levels. Here, we study the eﬀect of full-length PrPC in Cu2+ inhibition of P2X4 receptor when both are coexpressed. PrPC
expressiondoesnotsigniﬁcantlychangetheATPconcentration-responsecurveinoocytesexpressingP2X4 receptors. However, the
presenceofPrPC reducestheinhibitionbyCu2+ oftheATP-elicitedcurrentsintheseoocytes,conﬁrmingourpreviousobservations
with the Cu2+ binding domain. Thus, our observations suggest a role for PrPC in modulating synaptic activity through binding of
extracellular Cu2+.
1.Introduction
Prion diseases are a group of fatal neurodegenerative disor-
ders that are sporadic, inherited, or transmissible [1]. These
include kuru and Creutzfeldt-Jakob disease in humans,
scrapie in sheep and bovine spongiform encephalopathy in
cattle. These pathologies are caused by the conformational
transition of the native and predominantly α-helical cellular
prion protein (PrPC) into a signiﬁcantly more β-sheet-
containing pathogenic isoform (PrPSc)[ 2], which unlike
PrPC, is insoluble in mild detergents and partially resistant
to digestion with proteinase K [3]. PrPC is a cell surface
glycosylphosphatidylinositol-anchoredproteinthatismainly
expressed in neurons and glial cells and to a lesser extent
in several peripheral tissues [4, 5]. The normal physiological
functionofPrPC remainselusive,althoughithasbeenrelated
tosignaling,neuroprotection,neuritogenesis,synaptictrans-
mission, oxidative stress, and copper metabolism [6–11].
PrPC binds copper ions with low micromolar aﬃnity
via histidine and glycine-containing peptide repeats in its
N-terminal region [12–17]. This Cu2+ binding domain is
located between residues 60–91 and consists of four identical
repeats of the peptide sequence Pro-His-Gly-Gly-Gly-Trp-
Gly-Gln. Although the number of octapeptide repeats varies
in diﬀerent species, in mammals this region is one of the
most highly conserved [18] and therefore, very likely deﬁnes
a functional domain of PrPC. In vitro, the octarepeat region
has the capacity to reduce Cu(II) to Cu(I) [19, 20]. In
addition, there is another Cu2+ binding site outside the
octarepeat region [21–24]o fh i g h e ra ﬃnity, in the order of
nanomolar, that involves His96 and His111 [24]. PrPC is
localized presynaptically at central synapses [25–27] and is
foundinsynapticmembranesandinsynapticvesicles[9,28].
Furthermore, PrPC-null mice show an impaired long-term
potentiation, suggesting that PrPC is involved in normal
synaptic function [10], and moreover, it has been shown2 International Journal of Alzheimer’s Disease
that PrPC is involved in regulating the presynaptic Cu2+
concentration and synaptic transmission [9].
The P2X family of nucleotide receptors forms non-
selective cationic channels activated by extracellular adeno-
sine triphosphate (ATP) [29] .T h e s er e c e p t o r sa r ew i d e l y
expressed in the central nervous system (CNS) [30–32]
and are involved in synaptic transmission and plasticity
including long-term potentiation as recently shown by us
[33]. Interestingly, trace metals modulate P2X receptors,
particularly, the P2X4 receptor subtype is diﬀerentially
modulated by trace metals at physiological concentrations
[34–37]. While Zn2+ facilitates the ATP-evoked currents,
Cu2+ inhibits it in a concentration-dependent manner [37].
Previously, we demonstrated that the N-terminal octarepeat
fragment of the PrPC prevents and reverses the inhibitory
actionofCu2+ ontheP2X4 receptorwhenaddedtothemedia
[38]. Herein, in an attempt to determine whether the PrPC-
Cu2+ interaction is relevant to synaptic activity, we extended
our investigations to test whether the full-length PrPCco-
expressed with the P2X4 receptor may modulate in situ the
Cu2+-induced inhibition of the ATP current gated by the
P2X4 receptor.
2.MaterialsandMethods
2.1. Drugs and Chemicals. Copper chloride, ATP (as the
tetrasodium salt), collagenase IA, and penicillin-streptomy-
cin were purchased from Sigma Chemical Co (St Louis, Mo).
AllthesaltsusedtopreparetheBarth’sincubationmediaand
the recording solutions were analytically graded and were
purchased from Merck (Darmstadt, Germany).
2.2. Oocyte Preparation, Injection, and Electrophysiological
Recordings. A segment of the Xenopus laevis ovary lobe was
surgically removed from adult anesthetized frogs; stages V-
VI oocytes were manually defolliculated and then incubated
with collagenase IA (1mg/mL) for 30min. Oocytes were
manually injected with 7.5–12.5ng cDNA coding for the
rat P2X4 receptor with or without cDNA coding for the
hamster prion protein (PrP-3F4), both cDNAs in plasmid
pcDNA3, at 250ng/μL. After 48–72h of incubation at
15◦C in Barth’s solution (in mM): 88 NaCl, 1 KCl, 2.4
NaHCO3, 10 HEPES, 0.82 MgSO4, 0.33 Ca(NO3)2,p H7 . 5 ,
supplemented with 10IU/L penicillin/10mg streptomycin,
oocytes were clamped at −70mV using the two-electrode
voltage clamp technique with an OC-725C oocyte clamper
(Warner Instrument Corp, Hamden, CT). ATP and CuCl2,
dissolved in Barth’s solution, were superfused at 2ml/min.
ATP-evoked currents were recorded with a 10s ATP exposure
appliedregularlyat10–15minintervals.Theseintervalswere
increased up to 25min for maximal ATP concentrations in
concentration-response curves protocols to decrease desen-
sitization. Copper was applied for 30s prior 10μMA T P
(coapplied with CuCl2).
2.3. Confocal Microscopy. To study the distribution of PrP,
oocytes were coinjected with the cDNA coding for the
rat P2X4 receptor with the cDNA coding for mouse PrP-
GFP(MmPrP-EGFP[25-266]-cDNA3).Oocytes,whereP2X4
receptor expression was validated electrophysiologically,
were directly analyzed on a Zeiss LSM 5 Pascal confocal
microscope.
2.4. Western Blotting. After electrophysiological protocols,
each oocyte injected with cDNa coding for P2X4 and PrP-
3F4 was homogenized for 30min in ice, using 40μLo f
lysis buﬀer per oocyte (100mM NaCl, 20mM Tris-HCl
pH 7.4, 1% Triton X-100) supplemented with a protease
inhibitorscocktail[39].Theextractswerecentrifugedfor30s
at 14000r.p.m. at 4◦C and the supernatant was removed and
resolvedby12%SDS-PAGEandtransferredtonitrocellulose.
Nonspeciﬁc binding sites were blocked with 5% (w/v) milk
in Tris-Buﬀered Saline (TBS) 0.1% Tween (TBST) for 1h.
After blocking, blots were incubated with monoclonal anti-
3F4 antibody [40], diluted 1:5000 in 3% (w/v) milk in
TBST for 1h at room temperature, followed by three 15min
washes in TBST at room temperature. The reactions were
followedbyincubationwithanti-mouseantibodyperoxidase
labeled (Pierce, Rockford, IL) and developed by enhanced
chemiluminescence.
2.5. Data Analysis. The average reduction of the ATP-gated
current was normalized. The ATP and Cu2+ concentration-
response curves were ﬁtted to a sigmoid function using the
GraphPad Prism software (San Diego, Cal). The median
eﬀective (EC50) or median inhibitory concentrations (IC50)
for ATP or copper, respectively, were interpolated from these
curves. Each protocol was performed in separate oocytes
coming from at least two separate batches of oocytes.
Mann-Whitney nonparametric Student’s t-test was used
for statistical analysis. A P value < 0.05 was considered
signiﬁcant.
3. Results
3.1. The Expression of PrP-3F4 Did Not Change the ATP
Concentration-ResponseCurveofP2X4 Receptors. To evaluate
whether the expression of PrPC modulates the inhibition of
the P2X4 receptor by Cu2+, we ﬁrst evaluated the expression
of PrPC in oocytes co-injected with the cDNA coding for
the hamster prion protein (PrP-3F4) and the cDNA coding
for the rat P2X4 receptor. Figure 1(a) shows the detection
by western blot of P2X4 receptor and PrP-3F4 using an
antibody that recognizes the 3F4 epitope [40]. β-Tubulin
detection was used as a loading control. As observed, both
proteins are strongly detected in an injected oocyte and
not in the control noninjected oocyte. Then we analyzed
the distribution of PrPC in oocytes co-injected with the
cDNA coding for the rat P2X4 receptor and the cDNA
codingforPrP-GFP.OocytesinwhichtheexpressionofP2X4
receptor was veriﬁed electrophysiologically were analyzed in
a confocal microscope to study the localization of PrP-GFP.
As observed in Figure 1(b),PrP-GFPislocatedonthesurface
of injected oocytes.
Then, we evaluated the ATP concentration-response
curves in oocytes expressing the P2X4 receptor and coex-
pressing the P2X4 receptor and PrP-3F4. The presence of
PrP-3F4 caused a slight, but not signiﬁcant, reduction inInternational Journal of Alzheimer’s Disease 3
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Figure 1: Coexpression of P2X4 and PrPC in X. laevis oocytes. (a)
Westernblotoftotallysatefractionsfromanon-injectedoocyte(left
lane, 1) and from an oocyte co-expressing P2X4 receptor and PrP-
3F4 (right lane, 2). Numbers on the right are molecular weights in
kDa. (b) Fluorescence microscopy of an oocyte co-expressing P2X4
receptor and PrP-GFP (green), bar = 10μM.
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Figure 2: ATP concentration-response curves from oocytes
expressing P2X4 receptor (open circles) or co-expressing P2X4
receptor and PrP-3F4 (closed circles). Symbols are mean values ±
SEM, numbers in parenthesis are number of oocytes.
the potency of ATP, reﬂected as an increase in its EC50 from
11.2 ± 1.1μMf o rP2 X 4 alone to 45.2 ± 9.4μMf o rP 2 X 4/PrP-
3F4 (n = 4, P = 0.0571, Figure 2), this slight displacement
of ATP concentration-response curve in the presence of PrP-
3F4 could represent a minor regulation of PrP-3F4 on P2X4
receptor activity.
3.2. The Co-Expression of P2X4 Receptors and PrP-3F4 Par-
tially Prevents the Copper-Induced Inhibition of the ATP-
Evoked Currents. We assess the Cu2+-induced inhibition of
10μM ATP currents in oocytes expressing P2X4 receptors.
The magnitude of the inhibition by 10μMC u 2+, preapplied
during 30s, was 51.5 ± 5.3% of the 10μM ATP-evoked
currents (n = 14, Figures 3(a) and 3(b)). However, the
10μMC u 2+-induced inhibition was reduced only to 71.9 ±
5% of the 10μM ATP-evoked currents in oocytes co-
expressing P2X4 receptors and the PrP-3F4 (n = 12, P<0.05
compared to P2X4 alone, Figures 3(a) and 3(b)), showing
that PrP-3F4 prevented the Cu2+-induced inhibition of P2X4
receptors compared to the Cu2+ inhibition elicited in oocytes
expressing only this receptor. Furthermore, the presence of
PrP-3F4 in the oocytes caused a rightward displacement of
the Cu2+ concentration-response curve obtained in oocytes
expressing only P2X4 receptor, an IC50 of 11.5 ± 1.9μM
was obtained for P2X4 and 34.1 ± 7.6μMf o rP 2 X 4/PrP-
3F4 (n = 5–7, P<0.01, Figure 3(c)), conﬁrming that
PrP-3F4 prevented the Cu2+-induced inhibition not only at
low micromolar concentrations of Cu2+, but even at higher
physiological concentrations of the metal.
4. Discussion
Several functions have been attributed to PrPC, including
immunoregulation, signal transduction, copper binding,
neurite outgrowth, induction of apoptosis or prevention
of apoptosis against apoptotic stimuli, and others [41]. In
addition, PrPC has been related to synapse formation and
maintenance and synaptic transmission [9, 10, 42], although
the mechanisms by which it exerts its role is still unknown.
One of the proposed targets for PrPC in synapse is to
modulate Cu2+ homeostasis, based on a highly conserved
Cu2+-binding sequence located on its N-terminal domain,
which includes four identical repeats of the peptide sequence
Pro-His-Gly-Gly-Gly-Trp-Gly-Gln [12, 15, 16]. It is known
that PrPC binds Cu2+ with high aﬃnity [14–17], and the
octarepeat region of the human PrPC (PrP59−91)r e d u c e s
Cu(II) to Cu(I) in vitro, which depends on the tryptophan
residues present in the octapeptide repeats [19, 20]. Cu2+
modulates synaptic transmission at micromolar concentra-
tions by a wide range of mechanisms, be one of the most rel-
evanting modulations of neurotransmitter receptors within
glutamatergic, gabaergic, and purinergic synapses, among
others [43, 44]. In a previous study, we demonstrated that
Cu2+ at micromolar concentrations inhibits the ATP-evoked
currents of P2X4 receptors [37]. Here we show that the full-
length prion protein-expressed in Xenopus oocytes localizes
in the cell surface and modulates the Cu2+ interaction with
P2X4 receptor; oocytes which coexpressed PrP-3F4 and P2X4
receptors have a diminished Cu2+-induced inhibition of the
ATP-evoked currents compared with oocytes which only
expressed the P2X4 receptor. This reduced inhibition by
Cu2+ was observed on Cu2+ concentration-response curves,
where the IC50 of Cu2+ was signiﬁcantly increased in the
presence of PrP-3F4, indicating that PrP-3F4 can exert its
modulatory role even at high micromolar concentrations
of Cu2+, reached in the synaptic cleft after depolarization
[45]. These results, together with our previous ﬁndings
showing that coapplication of Cu2+ with the N-terminal
PrP fragment (PrP59−91) prevents the inhibitory eﬀect of
copper on P2X4 receptors and even reverts the established
Cu2+-induced inhibition of the P2X4 receptors [38], strongly
support the idea that PrPC could modulate synaptic copper
and therefore aﬀect the function of P2X4 receptors and
synaptic transmission.
In addition to the potential synaptic role of PrPC
driven by its ability to bind Cu2+, a known modulator of4 International Journal of Alzheimer’s Disease
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Figure 3: PrPC prevents Cu2+-induced inhibition of P2X4 receptor. (a) Representative recordings obtained from oocytes expressing P2X4
receptor (left traces, P2X4) or coexpressing P2X4 receptor and PrP-3F4 (right traces, P2X4/PrP-3F4) showing 10μM ATP-evoked currents
(open bars) and its inhibition by 10μMC u 2+ (closed bars). (b) Statistical analysis of Cu2+ inhibition showed in (a), performed in diﬀerent
oocytes (n = 12–14, ∗P<0.01 versus ATP, #P<0.01 versus P2X4 alone). Bars are mean values ± SEM. (c), Cu2+ concentration-response
curves of 10μM ATP inhibition in oocytes expressing P2X4 receptor (open circles) or co-expressing P2X4 receptor and PrP-3F4 (closed
circles). Symbols are mean values ± SEM, numbers in parenthesis are number of oocytes.
neuronal excitability [43, 44], there is increasing evidence
of direct interaction between PrPC and neurotransmitter
receptors. PrPC directly interacts with the NR2D subunit of
the NMDA receptor, inhibiting it and preventing NMDA-
induced excitoxicity in the hippocampus [46]. On the other
hand,PrPC alsoexertsaneuroprotectiveroleagainstkainate-
induced neurotoxicity in the hippocampus, probably by
regulating diﬀerentially the expression of GluR6 and GluR7
kainatereceptorsubunits[47].Moreover,PrPC canmodulate
the activity of serotoninergic receptors signaling pathways
in 1C115−HT cells [48]. We observed a slight, although not
signiﬁcant, reduction on ATP aﬃnity of P2X4 receptor in
the presence of PrP-3F4, this might suggest an interference
with ATP binding or stabilization of closed states, although
further experiments are required to evaluate this hypothesis.
Altogether, these studies and the presented here highlight the
modulatory role of PrPC at synaptic transmission in CNS,
involving direct regulation of neurotransmitter receptorsInternational Journal of Alzheimer’s Disease 5
and/or their signaling cascade, or indirectly, by controlling
the synaptic levels of Cu2+.
The understanding of the physiological function of
PrPC on synaptic transmission may clarify the pathogenic
processesunderlyingpriondiseases.Basedonourresults,itis
possible to suggest that the resulting cognitive deterioration
of prion diseases could involve a loss of the modulatory role
ofPrPC onbrainfunction,asitisconvertedtothepathogenic
isoform.
Abbreviations
PrPC: Cellular prion protein
ATP: Adenosine triphosphate
CNS: Central nervous system
EC50: Median eﬀective concentration
IC50: Median inhibitory concentration.
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